Retinal Vein Occlusion (RVO): Symptoms, Types, and Treatment
Updated: Nov 13
Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026
Quick Answer: What is Retinal Vein Occlusion (RVO)?
Retinal vein occlusion (RVO) is a vascular disorder in which a blood clot or vessel compression blocks blood flow out of the retina, causing pressure, swelling and possible vision loss. It is the second most common retinal blood vessel disorder after diabetic retinopathy. Warning signs include sudden vision loss in one eye, and prompt diagnosis and treatment help preserve sight.

What the research says
Anti-VEGF injections improve vision. A Cochrane review found people with central retinal vein occlusion and macular swelling were 2.71 times more likely to gain at least 15 letters of vision at 6 months with anti-VEGF injections than with sham, and 80% less likely to lose 15 letters (Braithwaite et al., Cochrane Database Syst Rev, 2014) [3].
Steroid implants need fewer shots but trade off results. A meta-analysis of 16 studies found a dexamethasone implant gave about 6.6 fewer letters of vision gain than anti-VEGF and higher risks of raised eye pressure and cataract (Ming et al., BMJ Open, 2020) [4].
RVO is common worldwide, and high blood pressure is its strongest risk factor. A systematic review and meta-analysis estimated that RVO affected 16.4 million people worldwide in 2008 and that, in 2015, 0.77% of people aged 30 to 89 had any RVO (0.64% branch, 0.13% central), about 28.06 million people; hypertension carried the highest risk (odds ratio 2.82, 95% CI 2.12 to 3.75) (Song et al., J Glob Health, 2019) [6].
Anti-VEGF injections improved vision in branch RVO. In a sham-controlled trial of 397 patients with macular edema after branch RVO, monthly ranibizumab improved vision by a mean of 16.6 letters (0.3 mg) and 18.3 letters (0.5 mg) at 6 months versus 7.3 letters with sham injections (P < 0.0001), and 55.2% and 61.1% of treated patients gained at least 15 letters versus 28.8% with sham (Campochiaro et al., Ophthalmology, 2010) [7].
In central RVO, two anti-VEGF drugs worked about equally well. In the SCORE2 trial of 362 patients with macular edema from central or hemiretinal vein occlusion, bevacizumab was noninferior to aflibercept: mean vision scores at month 6 were 69.3 in both groups, a gain of 18.6 and 18.9 letters (Scott et al., JAMA, 2017) [8].
What is Retinal Vein Occlusion?
Retinal Vein Occlusion (RVO) occurs when one of the veins responsible for carrying blood away from the retina becomes partially or totally blocked. The retina is the light-sensitive tissue at the back of the eye that converts light into the signals your brain uses to create images. When a vein is blocked, blood cannot leave the eye properly, leading to a backup of blood and fluid, higher pressure inside the retinal veins, and swelling.
There are two primary forms of this condition:
Central Retinal Vein Occlusion (CRVO): A blockage in the main vein that drains the entire retina.
Branch Retinal Vein Occlusion (BRVO): A blockage in one of the smaller veins branching off the main vessel. BRVO is the more common type.
Worldwide, CRVO affects between 1 and 4 in 1,000 people, and BRVO affects between 6 and 12 in 1,000 people. [5]
What are the symptoms and warning signs of retinal vein occlusion (RVO)?
RVO typically affects only one eye. The symptoms can vary depending on the severity of the blockage and whether complications have already developed.
Some people have no symptoms until complications develop. [5]
Blurry Vision: This is the most common symptom and may occur suddenly or develop over several days.
Vision Loss: A partial or complete loss of sight in the affected eye.
Eye Floaters: The appearance of dark spots, lines, or "cobwebs" in your field of vision.
Eye Pain or Pressure: Typically seen in advanced cases where internal eye pressure has risen significantly.
What causes retinal vein occlusion, and who is at risk?
RVO is caused by a disruption in normal blood flow. This can happen if a blood clot forms in the vein or if a nearby artery, stiffened by age or plaque, compresses the vein.
A slowdown of blood flow in the vein can also lead to a blockage. [5]
Risk Factor | Why it Matters |
|---|---|
Age | Most cases occur in people over 50, though it can affect younger adults. |
High Blood Pressure | Hypertension is a leading contributor to vessel damage and compression. |
Diabetes | High blood sugar can damage the delicate blood vessels in the eye. |
Atherosclerosis | Hardening of the arteries increases the risk of vein compression. |
Glaucoma | Increased eye pressure can contribute to vascular blockages. |
Being over age 40 is a major risk factor, and RVO usually affects people in their 50s or 60s. [5] A previous retinal vein occlusion in one eye also raises your risk. [5]
What complications can retinal vein occlusion cause?
Untreated retinal vein occlusion can lead to serious complications, including macular edema, abnormal vessel growth, vitreous hemorrhage, neovascular glaucoma and retinal detachment.
Macular Edema: Swelling in the center of the retina (the macula), causing blurred central vision. [3]
Neovascularization: The growth of abnormal, fragile blood vessels that are prone to leaking.
Vitreous Hemorrhage: Bleeding into the gel-like substance that fills the eye.
Neovascular Glaucoma: A painful increase in eye pressure caused by abnormal vessel growth.
Retinal Detachment: In severe cases, abnormal vessels can pull the retina away from the back of the eye.
Abnormal new blood vessels typically grow in the iris, which happens in about 1 in 4 people with RVO. [5]

How is retinal vein occlusion diagnosed and tested?
Eye care specialists use several advanced imaging tools to diagnose RVO and assess the extent of the damage.
Dilated Eye Exam: Using drops to widen the pupil, the doctor examines the retina for signs of blockage or bleeding.
Optical Coherence Tomography (OCT): A high-resolution scan that measures retinal thickness and identifies macular edema.
Fluorescein Angiography: A dye is injected into the arm to highlight the blood vessels in the retina, showing exactly where the blockage is located.
Fundus Photography: Detailed photos of the back of the eye to document abnormal vessel growth and bleeding.
Eye specialists also coordinate care with your primary care physician to look for the cause, which may include blood tests for cholesterol and blood sugar. [5]
How is retinal vein occlusion treated and managed?
The original retinal vein occlusion usually cannot be cleared, so treatment with injections, laser or surgery focuses on managing complications and protecting remaining vision.
Medical Injections
Anti-VEGF Injections: These medications block a protein (VEGF) that causes abnormal blood vessel growth and leakage. This is the primary treatment for macular edema.
Steroid Injections: Used to reduce inflammation and swelling in the retina. [4]
Anti-VEGF medicines include aflibercept, bevacizumab and ranibizumab, and injections may continue for one to two years. [5] In some people, steroid injections can raise eye pressure and cause cataracts. [5]
Surgical and Laser Procedures
Vitrectomy is used for severe bleeding, bleeding that lasts more than four weeks or keeps coming back, and retinal detachment. [5] Your primary care physician may also prescribe medicines to lower blood pressure or manage cholesterol. [5]
Outlook varies: some people have permanent vision damage, while others see their vision improve gradually. [5]

Conclusion
Retinal Vein Occlusion is a serious vascular condition that can significantly impact your vision. While the blockage itself is often permanent, modern medical interventions are highly successful at preventing further damage and managing complications like swelling and bleeding. Early detection through regular eye exams is the most effective way to protect your sight.
What are the next steps if you have retinal vein occlusion?
If you notice any sudden changes in your vision, see an eye specialist immediately. Managing underlying health conditions like high blood pressure and diabetes is critical for preventing RVO in your other eye and reducing the risk of systemic issues like stroke.
Frequently Asked Questions
1. Can Retinal Vein Occlusion be cured?
There is no current way to unblock the vein, but the complications (like swelling and bleeding) can be treated effectively to save your vision.
2. Is RVO a sign of a stroke?
While RVO is a blockage in the eye, people with RVO have a higher risk of cardiovascular issues, including stroke, due to shared risk factors like high blood pressure.
3. Does RVO affect both eyes?
RVO usually affects only one eye at a time, but having it in one eye increases the risk of it developing in the other eye later.
4. What is the difference between CRVO and BRVO?
CRVO is a blockage of the main retinal vein, while BRVO is a blockage of a smaller branch vein. BRVO is generally more common.
5. How long do the injections last?
Anti-VEGF injections are often given in a series, sometimes monthly, depending on how your eye responds to the treatment.
6. Will my vision ever return to normal?
Many patients experience significant improvement with treatment, but the final outcome depends on the severity of the blockage and how quickly treatment began.
7. Can I prevent RVO?
You can lower your risk by managing high blood pressure, cholesterol, and diabetes, and by not smoking.
8. Is laser treatment painful?
Most patients experience only mild discomfort during laser procedures. Your doctor will use numbing drops or local anesthesia.
9. What are floaters?
Floaters are small spots or lines in your vision caused by clumps in the eye's gel or bleeding from abnormal vessels.
10. Can high eye pressure cause RVO?
Yes, conditions like glaucoma that increase internal eye pressure are known risk factors for vein occlusion.
11. What is macular edema?
Macular edema is the buildup of fluid and swelling in the macula, the part of the retina responsible for sharp, central vision. Read more in our guide to cystoid macular edema.
12. How is RVO diagnosed?
RVO is diagnosed through a dilated eye exam and imaging tests like OCT and fluorescein angiography.
13. What happens if RVO is left untreated?
Untreated RVO can lead to permanent vision loss, neovascular glaucoma, and retinal detachment.
14. Are there side effects to the injections?
Common side effects include temporary eye irritation or a feeling of something in the eye. Serious complications like infection are very rare.
15. Should I see my regular doctor too?
Yes. Your eye specialist will likely coordinate with your primary care physician to manage underlying risks like hypertension.
Related Reading
Fluorescein Angiography: How the Eye Dye Test Works, How to Prepare and What Results Mean explains the eye dye test that shows changes in the retina's blood vessels.
Trusted External Resources
References
Mayo Clinic Staff. Retinal diseases - Symptoms and causes. Mayo Clinic. March 8, 2024. https://www.mayoclinic.org/diseases-conditions/retinal-diseases/symptoms-causes/syc-20355825
Mayo Clinic Staff. Retinal diseases - Diagnosis and treatment. Mayo Clinic. March 8, 2024. https://www.mayoclinic.org/diseases-conditions/retinal-diseases/diagnosis-treatment/drc-20355827
Braithwaite T, Nanji AA, Lindsley K, et al. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2014;2014(5):CD007325. PMID 24788977. https://doi.org/10.1002/14651858.CD007325.pub3
Ming S, Xie K, Yang M, et al. Comparison of intravitreal dexamethasone implant and anti-VEGF drugs in the treatment of retinal vein occlusion-induced oedema: a meta-analysis and systematic review. BMJ Open. 2020;10(6):e032128. PMID 32595145. https://doi.org/10.1136/bmjopen-2019-032128
Cleveland Clinic. Retinal Vein Occlusion (RVO). Cleveland Clinic. Last updated June 19, 2023. https://my.clevelandclinic.org/health/diseases/14206-retinal-vein-occlusion-rvo
Song P, Xu Y, Zha M, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019;9(1):010427. PMID 31131101. https://doi.org/10.7189/jogh.09.010427
Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-1112.e1. PMID 20398941. https://doi.org/10.1016/j.ophtha.2010.02.021
Scott IU, VanVeldhuisen PC, Ip MS, et al. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA. 2017;317(20):2072-2087. PMID 28492910. https://doi.org/10.1001/jama.2017.4568
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.




Comments